Edition:
United States

ImmunoCellular Therapeutics Ltd (IMUC.A)

IMUC.A on American Stock Exchange

0.12USD
30 Sep 2016
Change (% chg)

$-0.00 (-0.25%)
Prev Close
$0.12
Open
$0.12
Day's High
$0.12
Day's Low
$0.12
Volume
34,413
Avg. Vol
206,909
52-wk High
$0.53
52-wk Low
$0.11

IMUC.A

Chart for IMUC.A

About

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $15.10
Shares Outstanding(Mil.): 127.95
Dividend: --
Yield (%): --

Financials

  IMUC.A Industry Sector
P/E (TTM): -- 43.83 36.83
EPS (TTM): -0.21 -- --
ROI: -76.76 -0.29 13.93
ROE: -92.81 -2.99 14.84

BRIEF-Immunocellular Therapeutics reports Q2 loss per share $0.06

* Immunocellular Therapeutics announces second quarter 2016 financial results

Aug 22 2016

BRIEF-Immunocellular Therapeutics files for non-timely 10-Q

* Expects to report a net loss of $5.3 million for three months ended June 30, versus $3.2 million for three months ended june 30, 2015 Source text for Eikon: Further company coverage:

Aug 16 2016

BRIEF-Immunocellular Therapeutics announces pricing of $7.4 mln public offering

* Total expected gross proceeds to Immunocellular of approximately $7.4 million

Aug 09 2016

BRIEF-Electronics For Imaging Inc reports Q2 revenue of $246 mln

* Q2 earnings per share view $0.58 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Jul 25 2016

BRIEF-ImmunoCellular Therapeutics treats first patient in ICT-107 phase 3 trial

* Reached agreement with FDA on special protocol assessment relative to primary, secondary endpoints and statistical plan for phase 3 trial

Jun 07 2016

BRIEF-Immunocellular Therapeutics Q1 loss per share $0.06

* Immunocellular therapeutics announces first quarter 2016 financial results

May 12 2016

BRIEF-Immunocellular receives regulatory nod to start ICT-107 phase 3 trial

* Receives regulatory approval in Canada, the UK and the Netherlands to initiate ICT-107 Phase 3 trial in newly diagnosed glioblastoma

May 06 2016

Earnings vs. Estimates